Keisuke Noda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keisuke Noda has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Keitaro Matsumoto
Division of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
4 shared publications - Takashi Nonaka
Division of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
4 shared publications - Hidetoshi Fukuoka2 shared publications
- Hiroaki Takeshita2 shared publications
- Hirokazu Kurohama
Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
2 shared publications - Hiroki Katayama2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Wiley in Pathology International
- Vol. 76 (11)
Reduced ZO‐1 Expression Is Associated With Structural Atypia in Gastric Crawling‐Type Adenocarcinoma
Gastric crawling‐type adenocarcinoma (CRA) is characterized by the lateral spread of low‐grade neoplastic glands and is frequently accompanied by poorly cohesive carcinoma (PCC) components. However, the molecular basis of its distinctive architecture remains unclear. We investigated the association of E‐cadherin and ZO‐1 expression with CRA and PCC components in 54 moderately differentiated intramucosal gastric tubular adenocarcinomas (22 CRA and 32 non‐CRA). Immunohistochemistry and quantitative multiplex immunofluorescence were used to assess E‐cadherin and ZO‐1 expression in non‐neoplastic mucosa, gland‐forming main tumor components, and PCC components. PCC components were more frequent in CRA than in non‐CRA lesions (50.0% vs. 6.3%, p = 0.001). E‐cadherin was reduced in main tumor components regardless of CRA status. ZO‐1 reduction was more frequent in CRA than in non‐CRA (90.9% vs. 18.8%, p < 0.001); quantitatively, main tumor components of CRA lesions showed lower ZO‐1 expression than main tumor components of non‐CRA lesions ( p < 0.001). Within CRA, PCC components showed lower ZO‐1 expression than corresponding main tumor components ( p < 0.014). Multivariable analysis identified reduced ZO‐1 expression as independently associated with CRA. These findings suggest that altered apicolateral junctional organization may contribute to the structural atypia of CRA and its association with PCC components.
- 18 November 2026
- Published by Wiley in Pathology International
- Vol. 76 (11)
Open AccessReduced ZO‐1 Expression Is Associated With Structural Atypia in Gastric Crawling‐Type Adenocarcinoma
Gastric crawling‐type adenocarcinoma (CRA) is characterized by the lateral spread of low‐grade neoplastic glands and is frequently accompanied by poorly cohesive carcinoma (PCC) components. However, the molecular basis of its distinctive architecture remains unclear. We investigated the association of E‐cadherin and ZO‐1 expression with CRA and PCC components in 54 moderately differentiated intramucosal gastric tubular adenocarcinomas (22 CRA and 32 non‐CRA). Immunohistochemistry and quantitative multiplex immunofluorescence were used to assess E‐cadherin and ZO‐1 expression in non‐neoplastic mucosa, gland‐forming main tumor components, and PCC components. PCC components were more frequent in CRA than in non‐CRA lesions (50.0% vs. 6.3%, p = 0.001). E‐cadherin was reduced in main tumor components regardless of CRA status. ZO‐1 reduction was more frequent in CRA than in non‐CRA (90.9% vs. 18.8%, p < 0.001); quantitatively, main tumor components of CRA lesions showed lower ZO‐1 expression than main tumor components of non‐CRA lesions ( p < 0.001). Within CRA, PCC components showed lower ZO‐1 expression than corresponding main tumor components ( p < 0.014). Multivariable analysis identified reduced ZO‐1 expression as independently associated with CRA. These findings suggest that altered apicolateral junctional organization may contribute to the structural atypia of CRA and its association with PCC components.
- Open Access
- 31 October 2026
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 42 (5) , 524-533
Oncological outcomes of robotic versus laparoscopic colectomy for colon cancer: a propensity score–matched study focusing on peritoneal recurrence
Purpose: To compare perioperative and oncologic outcomes between robotic and laparoscopic colectomy for colon cancer, with a focus on peritoneal recurrence, using a propensity score–matched analysis.Methods: We retrospectively reviewed 591 patients who underwent minimally invasive colectomy for colon cancer between 2016 and 2024. After 1:1 propensity score matching based on age, sex, body mass index, American Society of Anesthesiologists physical status, clinical stage, and procedure, 90 patients in each group were analyzed. Survival outcomes were assessed using Kaplan-Meier methods and competing risk analysis with the Fine-Gray model.Results: Robotic colectomy showed lower blood loss (median, 10 mL vs. 20 mL; P<0.001), shorter postoperative hospital stay (median, 9 days vs. 11.5 days, P<0.001), and a higher rate of intracorporeal anastomosis (92.2% vs. 24.4%, P<0.001), without prolonging operative time. Disease-free survival was comparable (P=0.519). Locoregional/peritoneal recurrence-free survival was higher in the robotic group (P=0.037); however, competing risk analysis using the Fine-Gray model showed no significant difference in the cumulative incidence of locoregional/peritoneal recurrence between groups. Multivariable analysis identified high-grade histology as an independent predictor of peritoneal recurrence, whereas surgical approach was not.Conclusion: Robotic colectomy provides favorable perioperative outcomes while maintaining oncologic safety comparable to laparoscopic colectomy. Peritoneal recurrence appears to be driven primarily by tumor biology, and intracorporeal anastomosis does not increase recurrence risk.
- 31 October 2026
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 42 (5) , 524-533
Open AccessOncological outcomes of robotic versus laparoscopic colectomy for colon cancer: a propensity score–matched study focusing on peritoneal recurrence
Purpose: To compare perioperative and oncologic outcomes between robotic and laparoscopic colectomy for colon cancer, with a focus on peritoneal recurrence, using a propensity score–matched analysis.Methods: We retrospectively reviewed 591 patients who underwent minimally invasive colectomy for colon cancer between 2016 and 2024. After 1:1 propensity score matching based on age, sex, body mass index, American Society of Anesthesiologists physical status, clinical stage, and procedure, 90 patients in each group were analyzed. Survival outcomes were assessed using Kaplan-Meier methods and competing risk analysis with the Fine-Gray model.Results: Robotic colectomy showed lower blood loss (median, 10 mL vs. 20 mL; P<0.001), shorter postoperative hospital stay (median, 9 days vs. 11.5 days, P<0.001), and a higher rate of intracorporeal anastomosis (92.2% vs. 24.4%, P<0.001), without prolonging operative time. Disease-free survival was comparable (P=0.519). Locoregional/peritoneal recurrence-free survival was higher in the robotic group (P=0.037); however, competing risk analysis using the Fine-Gray model showed no significant difference in the cumulative incidence of locoregional/peritoneal recurrence between groups. Multivariable analysis identified high-grade histology as an independent predictor of peritoneal recurrence, whereas surgical approach was not.Conclusion: Robotic colectomy provides favorable perioperative outcomes while maintaining oncologic safety comparable to laparoscopic colectomy. Peritoneal recurrence appears to be driven primarily by tumor biology, and intracorporeal anastomosis does not increase recurrence risk.
- Open Access
- 31 August 2026
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 42 (4) , 407-414
Surgical and oncologic outcomes of cT4b rectal cancer: a propensity score–matched comparison between a university center and regional hospitals
Purpose: Surgery for cT4b rectal cancer remains technically demanding, and outcomes may vary substantially across institutions. This study evaluated perioperative and oncologic outcomes of cT4b rectal cancer surgery performed at a university center compared with those at regional hospitals within a collaborative network.Methods: A total of 103 patients who underwent curative-intent surgery for cT4b rectal cancer between 2016 and 2024 were retrospectively reviewed. After 1:1 propensity score matching based on baseline characteristics and treatment factors, 54 patients were included in the analysis. Perioperative outcomes, pathological findings, and long-term oncologic outcomes were compared between the university hospital and affiliated regional institutions. Overall survival, relapse-free survival, and local control rate were additionally evaluated in patients with pathological stage II–III disease.Results: Postoperative hospital stay was significantly shorter at the university center (18 days vs. 25 days, P=0.022). Local control was higher in the university hospital group (3-year local control rate: 95.2% vs. 71.5%, P=0.025). Among patients with pathological stage II–III disease, 3-year relapse-free survival was comparable between groups (51.8% vs. 49.0%, P=0.434), whereas local control demonstrated a favorable trend in the university hospital group (91.7% vs. 65.4%, P=0.063).Conclusion: Perioperative safety in cT4b rectal cancer surgery was comparable across institutions; however, higher local control at the university center suggests that technically complex cases may benefit from selective centralization in specialized centers. These findings support a hybrid model in which regional collaboration ensures safety while advanced procedures are concentrated in specialized centers.
- 31 August 2026
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 42 (4) , 407-414
Open AccessSurgical and oncologic outcomes of cT4b rectal cancer: a propensity score–matched comparison between a university center and regional hospitals
Purpose: Surgery for cT4b rectal cancer remains technically demanding, and outcomes may vary substantially across institutions. This study evaluated perioperative and oncologic outcomes of cT4b rectal cancer surgery performed at a university center compared with those at regional hospitals within a collaborative network.Methods: A total of 103 patients who underwent curative-intent surgery for cT4b rectal cancer between 2016 and 2024 were retrospectively reviewed. After 1:1 propensity score matching based on baseline characteristics and treatment factors, 54 patients were included in the analysis. Perioperative outcomes, pathological findings, and long-term oncologic outcomes were compared between the university hospital and affiliated regional institutions. Overall survival, relapse-free survival, and local control rate were additionally evaluated in patients with pathological stage II–III disease.Results: Postoperative hospital stay was significantly shorter at the university center (18 days vs. 25 days, P=0.022). Local control was higher in the university hospital group (3-year local control rate: 95.2% vs. 71.5%, P=0.025). Among patients with pathological stage II–III disease, 3-year relapse-free survival was comparable between groups (51.8% vs. 49.0%, P=0.434), whereas local control demonstrated a favorable trend in the university hospital group (91.7% vs. 65.4%, P=0.063).Conclusion: Perioperative safety in cT4b rectal cancer surgery was comparable across institutions; however, higher local control at the university center suggests that technically complex cases may benefit from selective centralization in specialized centers. These findings support a hybrid model in which regional collaboration ensures safety while advanced procedures are concentrated in specialized centers.
- Open Access
- 12 August 2026
- Published by Wiley in Pathology International
- Vol. 76 (8) , e70164
Muir–Torre Syndrome Associated With a Cryptic Intronic MSH2 Variant Identified via Whole‐Genome Sequencing: A Case Report
Tumors exhibiting mismatch repair deficiency without detectable germline mutations via standard multigene panel testing are often classified as Lynch‐like syndrome. In the present report, we describe the case of a 47‐year‐old man presenting with synchronous axillary sebaceous carcinoma and colonic medullary carcinoma. Although initial germline multigene panel testing failed to identify pathogenic variants, a high degree of pathological suspicion for Muir–Torre syndrome remained. Immunohistochemistry revealed a concordant loss of MSH2 and MSH6 expression in both the extraocular sebaceous carcinoma and the colonic medullary carcinoma. This identical protein‐loss pattern detected across anatomically distinct tumors served as decisive pathological evidence of an underlying germline defect rather than independent biallelic somatic mutations. Consequently, whole‐genome sequencing was performed to resolve the discrepancy between the pathological findings and multigene panel testing results, successfully identifying a germline intronic MSH2 variant (NM_000251.3:c.2459‐12A>G). Subsequent RNA analysis confirmed aberrant splicing with an 11‐bp insertion. In conclusion, the present case illustrates that concordant mismatch repair protein loss across multiple tumors provides compelling morphological evidence to guide pathologists in reconsidering negative panel results and pursuing comprehensive genomic investigation to identify pathogenic intronic variants.
- 12 August 2026
- Published by Wiley in Pathology International
- Vol. 76 (8) , e70164
Open AccessMuir–Torre Syndrome Associated With a Cryptic Intronic MSH2 Variant Identified via Whole‐Genome Sequencing: A Case Report
Tumors exhibiting mismatch repair deficiency without detectable germline mutations via standard multigene panel testing are often classified as Lynch‐like syndrome. In the present report, we describe the case of a 47‐year‐old man presenting with synchronous axillary sebaceous carcinoma and colonic medullary carcinoma. Although initial germline multigene panel testing failed to identify pathogenic variants, a high degree of pathological suspicion for Muir–Torre syndrome remained. Immunohistochemistry revealed a concordant loss of MSH2 and MSH6 expression in both the extraocular sebaceous carcinoma and the colonic medullary carcinoma. This identical protein‐loss pattern detected across anatomically distinct tumors served as decisive pathological evidence of an underlying germline defect rather than independent biallelic somatic mutations. Consequently, whole‐genome sequencing was performed to resolve the discrepancy between the pathological findings and multigene panel testing results, successfully identifying a germline intronic MSH2 variant (NM_000251.3:c.2459‐12A>G). Subsequent RNA analysis confirmed aberrant splicing with an 11‐bp insertion. In conclusion, the present case illustrates that concordant mismatch repair protein loss across multiple tumors provides compelling morphological evidence to guide pathologists in reconsidering negative panel results and pursuing comprehensive genomic investigation to identify pathogenic intronic variants.
- 21 March 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (6) , 1183-1192
Survival paradox and effect of adjuvant chemotherapy for high-risk Stage II and low-risk Stage III colorectal cancer
Purpose High-risk Stage II may have a worse prognosis than low-risk Stage III colorectal cancer and there are limited reports examining the efficacy of adjuvant chemotherapy in Stage II and III subgroups. Methods Using a multicenter database, 598 colorectal cancer patients who underwent laparoscopic colorectal resection and were pathologically diagnosed with high-risk Stage II (T4N0) or low-risk Stage III (T1-2N1, T1-2N2, T3N1) between April 2016 and December 2022 were retrospectively reviewed. Results Fewer patients received adjuvant chemotherapy in the T4N0 group (54.7/45.0/44.7/27.7%, p < 0.001). The T4N0 group had significantly worse 5-year relapse-free survival (RFS) (67.0 vs. 95.5%, p < 0.01) and than the T1-2N1 group. The T4N0 group had significantly worse 5-year RFS (67.0% vs. 95.5%, p < 0.01) than the T1-2N1 group. Five-year OS was significantly better in the T1-2N1 and T3N1 groups with than without adjuvant chemotherapy (p < 0.032, p < 0.001, respectively), but not in the T4N0 group. Conclusions The present multicenter study showed that high-risk Stage II colorectal cancer may have a worse prognosis than low-risk Stage III colorectal cancer. Preoperative treatment may be considered for T4N0 colorectal cancer.
- 21 March 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (6) , 1183-1192
Survival paradox and effect of adjuvant chemotherapy for high-risk Stage II and low-risk Stage III colorectal cancer
Purpose High-risk Stage II may have a worse prognosis than low-risk Stage III colorectal cancer and there are limited reports examining the efficacy of adjuvant chemotherapy in Stage II and III subgroups. Methods Using a multicenter database, 598 colorectal cancer patients who underwent laparoscopic colorectal resection and were pathologically diagnosed with high-risk Stage II (T4N0) or low-risk Stage III (T1-2N1, T1-2N2, T3N1) between April 2016 and December 2022 were retrospectively reviewed. Results Fewer patients received adjuvant chemotherapy in the T4N0 group (54.7/45.0/44.7/27.7%, p < 0.001). The T4N0 group had significantly worse 5-year relapse-free survival (RFS) (67.0 vs. 95.5%, p < 0.01) and than the T1-2N1 group. The T4N0 group had significantly worse 5-year RFS (67.0% vs. 95.5%, p < 0.01) than the T1-2N1 group. Five-year OS was significantly better in the T1-2N1 and T3N1 groups with than without adjuvant chemotherapy (p < 0.032, p < 0.001, respectively), but not in the T4N0 group. Conclusions The present multicenter study showed that high-risk Stage II colorectal cancer may have a worse prognosis than low-risk Stage III colorectal cancer. Preoperative treatment may be considered for T4N0 colorectal cancer.